SOLUTIONS
Case Study
As Xeris Pharmaceuticals prepared to go public and brought its first FDA-approved product to market, the company faced rising complexity in managing its contract portfolio. With contracts stored in shared drives and tracked manually, the team lacked visibility, control, and audit-readiness. Rapid employee growth and strict compliance requirements—such as those mandated by the Sunshine Act and Insider Trading regulations—further heightened the need for a more robust, centralized contract management solution.
Xeris turned to ContractWorks – a member of the Onit portfolio, a secure and intuitive contract management platform, to bring structure and visibility to its growing contract operations. With ContractWorks, Xeris was able to:
By implementing ContractWorks, Xeris realized measurable improvements in efficiency, compliance, and internal controls:
Increased visibility and control over thousands of contracts with built-in reminders and milestone tracking.
Streamlined contract routing and approvals, reducing average turnaround time to just five days.
Improved regulatory compliance with automated tracking and reporting for internal policy acknowledgments and attestations.
Enhanced internal controls by enforcing legal and financial reviews prior to contract execution.
Scalable contract management capable of supporting rapid growth and regulatory demands post-IPO.
Empower department leadership by enabling real-time decision-making through personalized reporting for department heads.
Headquartered in Chicago, Illinois, Xeris Pharmaceuticals (Nasdaq: XERS) is a specialty pharmaceutical company focused on delivering innovative injectable and infusible therapies. With its proprietary XeriSol™ and XeriJect™ formulation technologies, Xeris provides room-temperature stable products designed to improve the patient experience and reduce healthcare system costs. The company’s commercial portfolio includes Gvoke®, an FDA-approved treatment for severe hypoglycemia.
Our Customers